跳到主要內容區

Exploring the Potential of Traditional Probiotics and Next-Generation Probiotics in Anti-Metabolic Syndrome Using Caenorhabditis elegans

學生姓名: 周立翔
指導教授: 陳詠宗
學期: 113上
摘  要: Metabolic syndrome primarily driven by obesity, is characterized by excessive accumulation or abnormal distribution of body fat. With the increasing prevalence of metabolic syndrome-associated diseases, innovative therapeutic strategies such as probiotics are urgently needed. This study employs a Caenorhabditis elegans model under high-glucose conditions to investigate the lipid metabolism regulatory potential of Pediococcus acidilactici CECT9879 (pA1c) (Traditional Probiotics) and pasteurized Akkermansia muciniphila (p-AKK) (Next-Generation Probiotics). Our results demonstrate that pA1c supplementation significantly reduces fat accumulation in C. elegans grown on nematode growth medium (NGM) and NGM supplemented with 10 mM glucose. Moreover, pA1c alleviates high-glucose-induced metabolic disturbances by decreasing reactive oxygen species (ROS) levels by 20% and delaying aging. Gene expression analysis reveals that pA1c regulates the insulin/IGF-1 signaling (IIS) pathway by reversing glucose-induced nuclear localization of daf-16, upregulating ins-6, daf-16, and fatty acid (FA) peroxisomal β-oxidation genes, while downregulating fatty acid synthesis genes. In parallel, p-AKK reduces fat accumulation and triglyceride levels by upregulating lipid hydrolysis and FA β-oxidation-related genes ( lipl-4, nhr-49, and acs27 2 ) while downregulating lipogenesis-related genes ( fat-7, elo-2, and men-1). These regulatory effects culminate in significantly diminished fat accumulation. These findings highlight the potential of pA1c and p-AKK as functional probiotics or live biotherapeutic products (LBPs) for modulating metabolic pathways to mitigate fat accumulation and address metabolic syndrome-associated disorders.
瀏覽數:
登入成功